(RVMD) Revolution Medicines - Overview
Stock: RAS Inhibitors, Companion Inhibitors
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 49.9% |
| Relative Tail Risk | -14.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.67 |
| Alpha | 107.11 |
| Character TTM | |
|---|---|
| Beta | 1.035 |
| Beta Downside | 0.995 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.63% |
| CAGR/Max DD | 1.13 |
Description: RVMD Revolution Medicines January 07, 2026
Revolution Medicines (NASDAQ: RVMD) is a clinical-stage precision-oncology firm that concentrates on “RAS-addicted” cancers. Its RAS(ON) inhibitor program targets mutant KRAS isoforms-including daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) and zoldonrasib G12D (RMC-9805)-all currently in Phase 1. The pipeline also includes next-generation candidates (RMC-5127 G12V, RMC-0708 Q61H, RMC-8839 G13C) and a suite of RAS companion agents such as RMC-4630 (Phase 2), the mTORC1-selective RMC-5552 (Phase 1), and the SOS1 inhibitor RMC-5845.
As of the most recent filing (Q4 2024), RVMD reported a market capitalization of roughly $1.1 billion and cash-and-equivalents of $210 million, giving the company an estimated 12-month runway at current burn rates. The global KRAS-targeted oncology market is projected to grow at a CAGR of 12-15 % through 2030, driven by the success of first-in-class KRAS G12C inhibitors (e.g., Amgen’s sotorasib) and the unmet need for G12D/G12V agents. Competitive pressure is high, but Revolution’s “RAS-ON” binding approach-aimed at maintaining KRAS in its active conformation-differs mechanistically from the “off-state” covalent inhibitors, potentially enabling synergistic combos and broader mutation coverage.
For a deeper quantitative view, the ValueRay platform offers a granular breakdown of RVMD’s valuation metrics and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -961.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -3.25 > 1.0 |
| NWC/Revenue: 662.0% < 20% (prev 197.9k%; Δ -197.2k% < -1%) |
| CFO/TA -0.34 > 3% & CFO -761.8m > Net Income -961.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (189.2m) vs 12m ago 13.42% < -2% |
| Gross Margin: -52.01% > 18% (prev -563.9%; Δ 51.2k% > 0.5%) |
| Asset Turnover: 13.03% > 50% (prev 0.04%; Δ 12.99% > 0%) |
| Interest Coverage Ratio: -82.39 > 6 (EBITDA TTM -1.00b / Interest Expense TTM 12.3m) |
Altman Z'' -5.99
| A: 0.77 (Total Current Assets 1.98b - Total Current Liabilities 245.6m) / Total Assets 2.25b |
| B: -1.11 (Retained Earnings -2.50b / Total Assets 2.25b) |
| C: -0.51 (EBIT TTM -1.02b / Avg Total Assets 2.01b) |
| D: -3.82 (Book Value of Equity -2.50b / Total Liabilities 655.0m) |
| Altman-Z'' Score: -5.99 = D |
What is the price of RVMD shares?
Over the past week, the price has changed by -3.86%, over one month by +22.52%, over three months by +61.76% and over the past year by +127.74%.
Is RVMD a buy, sell or hold?
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RVMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112.5 | 17.3% |
| Analysts Target Price | 112.5 | 17.3% |
| ValueRay Target Price | 126.4 | 31.7% |
RVMD Fundamental Data Overview February 01, 2026
P/B = 11.8892
Revenue TTM = 261.6m USD
EBIT TTM = -1.02b USD
EBITDA TTM = -1.00b USD
Long Term Debt = 158.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.3m USD (from shortTermDebt, last quarter)
Debt = 158.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.0m USD (from netDebt column, last quarter)
Enterprise Value = 16.97b USD (18.74b + Debt 158.5m - CCE 1.93b)
Interest Coverage Ratio = -82.39 (Ebit TTM -1.02b / Interest Expense TTM 12.3m)
EV/FCF = -21.84x (Enterprise Value 16.97b / FCF TTM -777.1m)
FCF Yield = -4.58% (FCF TTM -777.1m / Enterprise Value 16.97b)
FCF Margin = -297.1% (FCF TTM -777.1m / Revenue TTM 261.6m)
Net Margin = -367.4% (Net Income TTM -961.0m / Revenue TTM 261.6m)
Gross Margin = -52.01% ((Revenue TTM 261.6m - Cost of Revenue TTM 397.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.54 (Enterprise Value 16.97b / Total Assets 2.25b)
Interest Expense / Debt = 7.21% (Interest Expense 11.4m / Debt 158.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -802.3m (EBIT -1.02b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.05 (Total Current Assets 1.98b / Total Current Liabilities 245.6m)
Debt / Equity = 0.10 (Debt 158.5m / totalStockholderEquity, last quarter 1.60b)
Debt / EBITDA = 0.06 (negative EBITDA) (Net Debt -59.0m / EBITDA -1.00b)
Debt / FCF = 0.08 (negative FCF - burning cash) (Net Debt -59.0m / FCF TTM -777.1m)
Total Stockholder Equity = 1.95b (last 4 quarters mean from totalStockholderEquity)
RoA = -47.87% (Net Income -961.0m / Total Assets 2.25b)
RoE = -49.25% (Net Income TTM -961.0m / Total Stockholder Equity 1.95b)
RoCE = -48.13% (EBIT -1.02b / Capital Employed (Equity 1.95b + L.T.Debt 158.5m))
RoIC = -41.11% (negative operating profit) (NOPAT -802.3m / Invested Capital 1.95b)
WACC = 9.70% (E(18.74b)/V(18.90b) * Re(9.73%) + D(158.5m)/V(18.90b) * Rd(7.21%) * (1-Tc(0.21)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 44.02%
Fair Price DCF = unknown (Cash Flow -777.1m)
EPS Correlation: -10.01 | EPS CAGR: 17.80% | SUE: 4.0 | # QB: 1
Revenue Correlation: -44.18 | Revenue CAGR: -64.22% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.65 | Chg30d=-0.006 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=-6.53 | Chg30d=-0.255 | Revisions Net=-4 | Growth EPS=-17.8% | Growth Revenue=+792.8%